SteineckI, CederholmJ, EliassonB, RawshaniA, Eeg-OlofssonK, SvenssonA-M, et al.Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study. BMJ, 2015; 350: h3234.
2.
BendingJJ, PickupJC, KeenH. Frequency of diabetic ketoacidosis and hypoglycemic coma during treatment with continuous subcutaneous insulin infusion. Am J Med, 1985; 79: 685–691.
3.
LinkeschovaR, RaoulM, BottU, BergerM, SpraulM. Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med, 2002; 19: 746–51.
4.
PickupJC, SuttonAJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections versus continuous subcutaneous insulin infusion. Diabetic Med, 2008; 25: 765–774.
5.
BruttomessoD, CostaS, BaritussioA. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy. Diabet Metab Res Rev, 2009; 25: 99–111.
6.
MillerKM, FosterNC, BeckRW, BergenstalRM, DuBoseSN, DiMeglioLA, et al.; for the T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the US: updated data from the T1D Exchange Clinic Registry. Diabetes Care, 2015; 38: 971–978.
DandonaP, ChaudhuriA, MohantyP, GhanimH. Anti-inflammatory effects of insulin. Curr Opin Clin Nutr Metab Care, 2007; 10: 511–517.
9.
JoshiN, CaputoGM, WeitekampMR, KarchmerAW. Infections in patients with diabetes mellitus. N Engl J Med, 1999; 341: 1906–1912.
10.
HauzenbergerJR, HipszerBR, LoeumC, McCuePA, DeStefanoM, TorjmanMC, et al.Detailed analysis of insulin absorption variability and the tissue response to continuous subcutaneous insulin infusion catheter implantation in swine. Diabetes Technol Ther, 2017; 19: 641–650.
11.
LevandoskiLA, WhiteNH, SantiagoJV. Localized skin reactions to insulin: insulin lipodystrophies and skin reactions to pumped subcutaneous insulin therapy. Diabetes Care, 1982; 5 (Suppl 1): 6–10.
12.
WongJC, BoyleC, DiMeglioLA, MastrandreaLD, AbelKL, CengizE, et al; T1D Exchange Clinic Network. Evaluation of pump discontinuation and associated factors in the T1D Exchange Clinic Registry. J Diabet Sci Technol, 2017; 11: 224–232.
13.
BorotS, FrancS, CristanteJ, PenfornisA, BenhamouPY, GuerciB, et al.; Diabeloop Study Group. Accuracy of a new patch pump based on a microelectromechanical system (MEMS) compared to other commercially available insulin pumps: results of the first in vitro and in vivo studies. J Diabet Sci Technol, 2014; 8: 1133–1141.
14.
van der HoogtM, van DykJC, DolmanRC, PietersM. Protein and fat meal content increase insulin requirement in children with type 1 diabetes—role of duration of diabetes. J Clin Translat Endocrinol, 2017; 10: 15–21.
15.
ReznikY, CohenO, AronsonR, CongetI, RunzisS, CastanedaJ, Lee SW; for the OpT2mise StudyGroup. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet, 2014; 384: 1265–1272.
16.
KerrD, MortonJ, Whately-SmithC, EverettJ, BegleyJP. Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J Diabet Sci Technol, 2008; 2: 450–455.
17.
PickupJC, YemaneN, BrackenridgeA, PenderS. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey. Diabet Technol Therapeut, 2014; 16: 145–149.
